# JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)

> **NIH NIH P30** · JOHNS HOPKINS UNIVERSITY · 2022 · $1,499,981

## Abstract

PROJECT SUMMARY – OVERALL
The mission of the JHU NIMH NeuroHIV Center for the past 15 years has been to catalyze and support
multidisciplinary high-impact science that addresses the NIH strategic plan for HIV research for addressing
comorbidities and complications in people with HIV (PWH). The Center has focused on developing novel
treatments to mitigate the impact of cognitive impairment in PWH by capitalizing on the investigative talents of
JHU thought leaders as well as its strong translational capabilities in drug discovery and development. The
Center has worked to promote NeuroHIV research partnerships within JHU, amongst NIMH HIV Centers and
across NIH supported NeuroHIV research programs. Through these interactions, the Center facilitated the
discovery of three novel first-in-class therapeutic agents which attracted commercial partners to translate
discovered therapeutics into the clinic. With respect to training, the Center has provided infrastructure for
mentoring the next generation of diverse NeuroHIV scientists. The Center’s new investigator training pipeline
has been extensive, ranging from high school seniors to senior faculty new to NeuroHIV, with a particular focus
on training scientists from under-represented minority populations. Most recently, in collaboration with other
NeuroHIV Centers, the JHU Center organized and led the highly regarded weekly virtual joint NIMH Center’s
Joint NeuroHIV Translational Seminar Series. For renewal, the JHU Center for the Advancement of HIV
Neurotherapeutics (JHU CAHN) was reconfigured to be a resource capable of facilitating clinical, biomarker,
and translational research that address a broader range of neurological and psychiatric complications in
NeuroHIV, not limited to cognitive impairment. This important thematic shift aligns with NIMH’s NeuroHIV related
research priorities to foster research that integrates central nervous system (CNS) complications more generally.
To accomplish this, we will capitalize on the NIMH Research Domain Criteria (RDoC) framework across the
Center’s Clinical, Biomarker and Therapeutic Cores, collaborations, and training efforts. These changes will help
pivot JHU CAHN toward a new model of innovation in therapeutic development, namely a personalized medicine
approach, developing and disseminating patient data-driven approaches to select therapeutic targets, identify
biomarkers, and predict individual treatment responses.

## Key facts

- **NIH application ID:** 10475436
- **Project number:** 2P30MH075673-16
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Norman J Haughey
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,499,981
- **Award type:** 2
- **Project period:** 2006-06-16 → 2027-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10475436

## Citation

> US National Institutes of Health, RePORTER application 10475436, JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN) (2P30MH075673-16). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10475436. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*